Data from eight patients in a small clinical trial have suggested that stem-cell therapy may be able to restore erectile function in men treated for prostate cancer by radical prostatectomy. … READ MORE …
Filed under: Uncategorized | Tagged: cell, ED, erectile, function, stem, therapy | 2 Comments »
On Monday December 11 (next week) phase I of the availability of generic Viagra will kick in (here in the US), and those of us who need / want this product to help cope with ED should see a roughly 50 percent drop in the price … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: ED, generic, sildenafil, Viagra | 3 Comments »
On our social network yesterday, a new member asked about a form of treatment called “GAINSWave” for men with erectile dysfunction (ED) after treatment for localized prostate cancer. We had never heard of GAINSWave prior to this question. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: dysfunction, ED, erectile, GAINSWave, LI-ESWT, low-intensity, shockwave | 3 Comments »
Data published on line in the Journal of Urology last December suggest that the new PDE5 inhibitor known as avanafil or Stendra® is supposedly effective in combating erectile dysfunction (ED) in just over one-third of men with ED at 6 months after bilateral, nerve-sparing radical prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: avanafil, ED, efficacy, erectile dysfunction, prostatectomy, safety | 7 Comments »
According to media information released earlier today by Vivus, Inc., the company’s selective, investigational phosphodiesterase type 5 (PDE5) inhibitor known as avanafil has shown positive results in a randomized, double-blind, multi-center, placebo-controlled Phase III clinical trial for the treatment of erectile dysfunction (ED) in patients after a radical prostatectomy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: avanafil, ED, erctile dysfunction, inhibitor, PDE5 | Leave a comment »
A recent report from John Mulhall’s group at Memorial Sloan-Kettering Cancer Center has provided data on the use of surgical implantation of penile prostheses for management of erectile dysfunction after treatment for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: ED, erectile dysfunction, implant, penile, prosthesis, surgery | 1 Comment »
It is unlikely to come as any big surprise to the average prostate cancer patient who was potent before first-line therapy but has erectile dysfunction (ED) afterward that there might be an association between ED and depression after initial treatment for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: depression, ED, erectile dysfunction | 6 Comments »
A new study from a German research group is likely to fuel concerns about some of the risks associated with prostate biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, complications, ED, erectile dysfunction, voiding | 12 Comments »
Today’s news reports include commentary on studies dealing with:
Filed under: Management, Treatment | Tagged: bounce, CyberKnife, ED, failure brachytherapy, LRP, lymphadenextomy, outcomes, PSA, RALP, robot-assisted laparoscopic prostatectomy, SBRT, sexual function, stereotactic body radiotherapy | Leave a comment »
A newly published report suggests that sexual function does indeed decline after external beam radiation therapy (EBRT) for prostate cancer — but only over the first 2 years post-treatment. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: EBRT, ED, erectile dysfucntion, external beam radiation therapy, sexual function | 2 Comments »
According to a company press release issued earlier today by VIVUS, Inc., avanafil, an investigational agent, was effective in the treatment of erectile dysfunction (ED) in some 77 percent of patients at a dose of 200 mg. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: avanafil, ED, erectile dysfunction | 5 Comments »
Risk for erectile dysfunction (ED) after prostate cancer treatment is commonly assumed to be a reason why many men avoid being tested for their risk for prostate cancer. Whether that is really true or not is actually not well understood. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: ED, erectile dysfunction, screening | Leave a comment »
A review article published last September on the relationship between erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) has just been defined by Faculty of 1000 Medicine as “changing clinical practice.” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ED, LUTS, PDE5 inhibitor | Leave a comment »
Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra) are now used regularly as a means to treat patients with erectile dysfunction (ED) following radiation therapy (RT) for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ED, erectile dysfunction, radiation therapy, sildenafil | 6 Comments »
After a relatively quiet news period, the flood gates have opened again, so we shall divide today’s news reports into two postings for easier reading. We have also published a separate report on the possibility of an association between alcohol use and prostate cancer diagnosis. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, aggressiveness, androgen resistance, avanafil, ED, erectile dysfunction, p63, prognosis, survival, vitamin D | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 